EMMUNE INC
Juno Beach, FL · Biotech · Private
eCD4-Ig, an antibody-based therapeutic that fuses CD4 domains and an HIV coreceptor-mimetic sulfopeptide to an antibody Fc region for HIV treatment and prevention
emmune.bio →- Grants
- $24M
- 31 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 13
- 2 granted · 11 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of a synthetic antibody based on the HIV receptor and co-receptor that is optimized for highly efficient killing of HIV-infected cells by ADCC | $223,934 | |
| Federal grant | Department of Health and Human Services · Phase II · Which Isotype Of ECD4-IG Most Effectively Suppresses Virus Replication? | $298,193 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Which Isotype Of ECD4-IG Most Effectively Suppresses Virus Replication? | $937,245 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Which Isotype Of ECD4-IG Most Effectively Suppresses Virus Replication? | $1,935,908 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of AAV vectors for long-term expression of eCD4-Ig | $299,239 | |
| Federal grant | Department of Health and Human Services · Phase I · Cpf1-mediated inactivation of an AAV transgene | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Which Isotype Of ECD4-IG Most Effectively Suppresses Virus Replication? | $998,663 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of AAV vectors for long-term expression of eCD4-Ig | $999,959 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of AAV vectors for long-term expression of eCD4-Ig | $999,675 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | $886,103 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of AAV vectors for long-term expression of eCD4-Ig | $999,443 | |
| Federal grant | Department of Health and Human Services · Phase II · Engineering AAV capsids for enhanced transduction of skeletal muscle | $292,899 | |
| Federal grant | Department of Health and Human Services · Phase II · Engineering AAV capsids for enhanced transduction of skeletal muscle | $32,101 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | $870,946 | |
| Federal grant | Department of Health and Human Services · Phase II · Glycoengineering eCD4-Ig | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Engineering AAV capsids for enhanced transduction of skeletal muscle | $1,012,172 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Glycoengineering eCD4-Ig | $974,663 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Glycoengineering eCD4-Ig | $1,974,663 | |
| Federal grant | Department of Health and Human Services · Phase II · Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig | $907,386 | |
| Federal grant | Department of Health and Human Services · Phase II · SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Process development for manufacturing eCD4-Ig | $299,998 | |
| Federal grant | Department of Health and Human Services · Phase I · Process development for manufacturing eCD4-Ig | $299,998 | |
| Federal grant | Department of Health and Human Services · Phase II · Glycoengineering eCD4-Ig | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Engineering AAV capsids for enhanced transduction of skeletal muscle | $1,012,172 | |
| Federal grant | Department of Health and Human Services · Phase II · SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Glycoengineering eCD4-Ig | $974,661 | |
| Federal grant | Department of Health and Human Services · Phase II · SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · IND-enabling studies for eCD4-Ig as a long-acting recombinant protein therapeutic | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Process development for manufacturing eCD4-Ig | $999,997 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1107 | VAXNEWMO, LLC | — | — |
| 1108 | EUGIT THERAPEUTICS, INC. | — | — |
| 1109 | Proximity Biosciences LLC | — | — |
| 1110 | EMMUNE INC | — | — |
| 1111 | EPPIN PHARMA, INC. | — | — |
| 1112 | DiaMedica Therapeutics Inc. | — | $110M |
| 1113 | JUN INNOVATIONS INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- ACE2 Muteins And Methods Of Using The Samegranted
- CD4 Muteins And Methods Of Using The Sameapplication
- CD4 Muteins And Methods Of Using The Samegranted
- Scaffolded Antigens And Engineered SARS-COV-2 Receptor-binding Domain (rbd) Polypeptidesapplication
- ACE2 Muteins And Methods Of Using The Sameapplication
- ACE2 Muteins And Methods Of Using The Sameapplication
- ACE2 Muteins And Methods Of Using The Sameapplication
- CD4 Muteins And Methods Of Using The Sameapplication
- Systems For Nucleic Acid Transferapplication
- Systems For Nucleic Acid Transferapplication
- Systems For Nucleic Acid Transferapplication
- Scaffolded Antigens And Engineered SARS-COV-2 Receptor-binding Domain (rbd) Polypeptidesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.